Insilico Medicine vs Tempus AI
Relationship
inClinico and Tempus Lens do comparable work on drug discovery; larger scale (public).
Assembled from the recorded fields for this pair, not hand-checked. The comparison below is read from each company’s own profile.
3 of 8 capabilities — Shares agent orchestration, data analysis and drug discovery.
Ludbee capability tags · from the product recordsShared product type — Both ship application.
Ludbee product recordsLarger scale — Tempus AI: $12.4B market cap, against Insilico Medicine's $4.3B market cap.
Ludbee scale figures · valuation, market cap or revenue estimateAligned comparison
Capability overlap
Shared · 3
Not verified for Tempus AI · 5
Recorded for Insilico Medicine. Tempus AI’s product records say nothing either way — a missing record is not a missing capability.
Not verified for Insilico Medicine · 1
Recorded for Tempus AI. Insilico Medicine’s product records say nothing either way — a missing record is not a missing capability.
Products, side by side
Algorithmic pairing — assembled from recorded fields, not hand-checked
Insilico Medicine
Application
AI research writing assistant that drafts structured, cited papers, reviews, grant proposals and abstracts against biomedical databases such as PubMed and bioRxiv.
Multimodal AI platform that forecasts the probability of success of individual clinical trials and scores alternative trial designs before implementation.
Tempus AI
Application
AI algorithm that identifies ECG signs associated with future atrial fibrillation risk.
AI algorithm that identifies ECG signs associated with low ejection fraction (heart-failure risk).
Clinical and genomic data platform that sequences patient samples and returns results to oncologists.
No counterpart
Insilico Medicine sells these in a stack layer with no product recorded for Tempus AI yet — nothing on the other side to compare them against.
Platform
AI platform for de novo design and multi-property optimization of peptides, nanobodies and antibodies against specified targets and epitopes.
Generative small-molecule design platform combining de novo generation with physics-based methods, retrosynthesis, ADMET profiling and custom model training.
Foundation-model training and benchmarking platform that fine-tunes a customer's own LLM on Insilico's proprietary pharma reasoning datasets and validates results in its automation lab.
AI platform for therapeutic target identification, biomarker discovery, indication prioritization and drug repurposing over a multi-omics knowledge base.
End-to-end generative-AI platform spanning target discovery, molecular design and clinical-trial risk assessment for pharmaceutical research.
Hardware
On-premise AI appliance running PandaOmics target and biomarker discovery locally with no external data transmission, sold in Server and Desktop editions.
Tempus AI sells these in a stack layer with no product recorded for Insilico Medicine yet — nothing on the other side to compare them against.
Agent platform
Agentic platform for oncology drug development that assembles patient cohorts, simulates trials and generates regulatory evidence from Tempus's real-world dataset.